Form 6-K TEVA PHARMACEUTICAL INDU For: Nov 15

Go back to Form 6-K TEVA PHARMACEUTICAL INDU For: Nov 15

Teva Pharma (TEVA) Tops Q3 EPS by 2c; Offers Q4 Outlook

November 15, 2016 7:01 AM EST

(Updated - November 15, 2016 7:05 AM EST)

Teva Pharma (NYSE: TEVA) reported Q3 EPS of $1.31, $0.02 better than the analyst estimate of $1.29. Revenue for the quarter came in at $5.56 billion versus the consensus estimate of $5.75 billion.

The company sees Q3 EPS of $1.34 - $1.44 with... More